BIOXYTRAN, INC (BIXT)
Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This compound is intended for tackling oxygen deprivation in the brain caused by strokes, as well as addressing wound hypoxia to avert tissue death and encourage recovery. Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-derived polysaccharide. This substance functions by attaching to and inhibiting galectin-1, a specific galectin, to treat mild to moderate instances of Covid-19. Established in 2008, the company maintains its main office in Newton, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Bioxytran, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.
USBioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people.
Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This compound is intended for tackling oxygen deprivation in the brain caused by strokes, as well as addressing wound hypoxia to avert tissue death and encourage recovery.
Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-derived polysaccharide. This substance functions by attaching to and inhibiting galectin-1, a specific galectin, to treat mild to moderate instances of Covid-19. Established in 2008, the company maintains its main office in Newton, Massachusetts.
Leadership
David Platt
Chairman, CEO, President & Secretary
Ola Soderquist CM&AA
CFO & Treasurer
Employees
3
Country
US
Sector
Healthcare
Website
bioxytraninc.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Hoberman Alan M | Director | Purchase | 210.0K | $126.0K | Nov 18, 2025 |
| Hoberman Alan M | Director | Grant/Award | 38.6K | $13.5K | Nov 14, 2025 |
 MILANOVA RADKA | Director | Grant/Award | 38.6K | $13.5K | Nov 14, 2025 |
 Utter Anders | Director | Grant/Award | 38.6K | $13.5K | Nov 14, 2025 |
 CONAWAY DALE H | Director | Grant/Award | 38.6K | $13.5K | Nov 14, 2025 |
| Hoberman Alan M | Director | Grant/Award | 10.4K | $5.1K | Aug 12, 2025 |
| Name | Shares | % | Source |
|---|---|---|---|
 PLATT DAVID CEO, Director, 10% Owner | 20.0M | 17.5% | FORM 4 |
 Sheikh Michael Chief Communications Officer | 8.2M | 7.2% | FORM 4 |
 Soderquist Ola CFO, 10% Owner | 500.0K | 0.4% | FORM 4 |
 CONAWAY DALE H Director | 379.2K | 0.3% | FORM 4 |
 Utter Anders Director | 372.6K | 0.3% | FORM 4 |
 Hoberman Alan M Director | 210.0K | 0.2% | FORM 4 |
 MILANOVA RADKA Director | 203.7K | 0.2% | FORM 4 |
Insiders
- Hoberman Alan MDirector
- MILANOVA RADKADirector
- Utter AndersDirector
- CONAWAY DALE HDirector
- Sheikh MichaelChief Communications Officer
- PLATT DAVIDCEO
- Soderquist OlaCFO
No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.
US30d Avg
69.86K
60d Avg
68.74K
90d Avg
103.11K